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Over the past decade, next-generation sequencing (NGS) has led to an exponential increase in our understanding of
the genetic basis of Mendelian diseases. NGS allows for the analysis of multiple regions of the genome in one single
reaction and has been shown to be a cost-effective and efficient tool in investigating patients with Mendelian diseases.
More recently, NGS has been successfully deployed in the clinics, with a reported diagnostic yield of ~25 %. However,
recommendations on clinical implementation of NGS are still evolving with numerous key challenges that impede the
widespread use of genetics in everyday medicine. These challenges include when to order, on whom to order, what
type of test to order, and how to interpret and communicate the results, including incidental findings, to the patient
and family. In this review, we discuss these challenges and suggest guidelines on implementing NGS in the routine
clinical workflow.
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Mendelian diseases, also known as monogenic diseases,
are disorders caused by mutations in one gene and
include diseases like thalassemia, cystic fibrosis, among
others. Mendelian diseases are considered to be rare
individually but collectively occur at a rate of 40 to 82
per 1000 live births, with an estimated 7.9 million chil-
dren being born annually with a serious birth defect of
genetic or partially genetic origin [1, 2]. These disorders
tend to run in families, although it has been found that a
significant number are caused by de novo events [3].
Depending on the pathomechanism, the phenotype is
manifested in a dominant (where one allele is mutated)
or recessive (where both alleles are mutated) manner
[4]. Of the estimated 20,000–25,000 protein-coding
genes in the human genome, mutations in 3348 genes
have been associated with Mendelian diseases [5].
Sanger sequencing, also known as the dideoxy method
[6], has been the gold standard in molecular diagnostics in
Mendelian diseases and remains the test of choice for clin-
ical genetic testing; the purpose of which is to confirm a* Correspondence: tanec@bigfoot.com
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creativecommons.org/publicdomain/zero/1.0/suspected diagnosis and allow more accurate genetic
counseling. However, Sanger sequencing can only analyze
one DNA segment at a time and is thus laborious and
time consuming. For diseases with genetic heterogeneity,
like retinitis pigmentosa, cardiomyopathy, and deafness, a
gene-by-gene Sanger sequencing approach has not been
shown to be economical or efficient [7].
Recent advances over the past decade have allowed for
high-throughput sequencing, and these advances are
collectively referred to as next-generation sequencing
(NGS). NGS has allowed for substantial increase in
sequencing content while dramatically reducing the cost
of sequencing per base. This allows for simultaneous
interrogation of multiple genes through one single reac-
tion and has been proven to be an effective alternative
for establishing the genetic basic of Mendelian diseases
in the research setting [8–11], and more recently, in the
clinical setting [12–16].
In this review, we shall aim to discuss the clinical util-
ity of NGS, including the opportunities and challenges
that arise from the clinical standpoint. We will also
focus our discussion on ways of implementing NGS in
the routine clinical workflow.ss article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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The process of NGS starts with extraction of DNA of an
individual, most commonly from peripheral leukocytes
obtained from blood sample but can be from another
tissue such as buccal swab or saliva. The DNA is then
broken down into short fragments and amplified using
polymerase chain reaction (PCR) or hybridization-based
approaches. The regions that are amplified could include
either a subset of genes (targeted approach) or all the
genes in the genome [9]. When sequencing all the genes,
if only the protein-coding regions are amplified, the
method is referred to as whole exome sequencing (WES).
However, if the target is the entire genome, then it is
known as whole genome sequencing (WGS).
These amplified products are then sequenced with the
use of one of the various sequencing technologies (e.g.,
Illumina’s sequencing by synthesis, Life Technologies’ se-
quencing by ligation, or Ion semiconductor sequencing)
to generate millions of short sequence reads. These se-
quences are then processed bioinformatically. First, they
are aligned to a reference genome (assembly) and then
compared for similarities and differences at each target
position. A list of variants (or differences in the se-
quence) is then generated, which is then filtered further,
to determine the significance of each of the variant. Com-
mon filters include rare or previously unreported variants,
variants that lead to altered function of the protein, and
variants previously reported to cause disease [17]. More
recently, algorithms that include the phenotypic informa-
tion in the variant analysis have been developed that aid
the clinician/researcher in narrowing down the candidate
gene list [18, 19].Next-generation sequencing in the clinical setting
Targeted vs whole exome sequencing
One of the biggest challenges clinicians are facing is
deciding between using targeted versus whole exome
sequencing. As the cost of sequencing continues to de-
crease, WES appears to be a more cost-effective ap-
proach. However, there are certain considerations before
embarking on one over the other.
Although exomes are supposed to cover the protein-
coding regions of the genome, the overall coverage tends
to be between 85–95 % only. This means that a particu-
lar gene of interest with respect to a specific phenotype
may not be covered, either completely or partially.
Reasons include poorly performing capture probes due
to high GC content, sequence homology, or repetitive
sequences. A targeted approach, on the other hand, has
a much higher or even complete coverage of all the
phenotype-specific genes by filling in the gaps with com-
plementary technologies such as Sanger sequencing or
long range PCR. For example, 4 of the 73 genes in ahearing loss panel are inadequately covered on WES but
are completely covered in a targeted panel [20].
Besides offering a more comprehensive coverage of the
“known” phenotype-specific genes, a targeted approach
also allows for deeper coverage of these genes compared
to WES, which provides greater confidence in the variants
detected. However, both are still prone to sequencing
artifacts, and Sanger sequencing of candidate variants is
recommended in both approaches before returning the
results to the patients [20].
Lastly, laboratories that offer targeted testing may have
expert knowledge for the given phenotype and may be in a
better position to prioritize variants detected through
NGS. They may also be able to recommend specific evalu-
ations to determine the significance of certain variants; for
example, temporal bone evaluation for SLC26A4 and
otoacoustic emission testing for OTOF when variants are
detected on a targeted hearing loss panel [20].
Indications and clinical usefulness
NGS is currently indicated for the detection of rare vari-
ants in patients with a phenotype suspected to be due to a
Mendelian disease. This is done either after single gene
testing for candidates has returned negative, or as first
line, if there exists genetic heterogeneity where multi-gene
Sanger sequencing would be costly and time consuming.
Diseases could either include a specific phenotype such as
cardiomyopathy, deafness, retinitis pigmentosa, intellec-
tual disability, or be part of a multiple congenital anomaly
spectrum (where two or more organs are affected) [21].
The clinical usefulness of performing NGS in the clin-
ical setting varies for different disorders. In the majority
of cases, the finding does not alter the clinical manage-
ment, treatment or prognosis. However, it does allow an
end to an expensive and stressful diagnostic odyssey.
Reaching a molecular diagnosis allows the clinician to
allay the guilt that parents face in the absence of a firm
diagnosis [13, 17] and helps them to accept the child’s
condition.
Identification of the causative variant allows for gene-
specific prognostication [22, 23], based on cases reported
in the literature and, in some cases, family support groups.
It can also allow for anticipatory management of other
comorbidities that an individual may be susceptible to.
These include assessing other organs (such as performing
blood tests and imaging to assess the heart and kidneys)
for possible complications. In some cases, it may redirect
therapy to treat the underlying genetic etiology as illus-
trated by the case of a 15-month-old child with clinical
presentation mimicking Crohn’s disease. WES revealed a
pathogenic variant in XIAP, affecting the proinflammatory
response and bacterial sensing, predisposing the individual
to developing hemophagocytosis. Based on these findings,
the child was successfully treated with hematopoietic bone
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intestinal disease as well [24].
More importantly, it facilitates genetic counseling and
allows for more accurate estimates of recurrence risk in
the family. Identification of the molecular etiology allows
the clinician to guide subsequent pregnancies, either
through prenatal diagnostics or preimplantation genetic
diagnosis. In some situations, it also allows for identifica-
tion of other at-risk family members and any available
treatment can be instituted in the presymptomatic phase
[17]. For example, identification of mutation in a gene
causing long QT syndrome in the proband can allow
identification of other at-risk family members, who can
then have regular Holter monitoring and, in some in-
stances, implantation of a cardiac pacemaker before a
catastrophic event occurs [25, 26].
Lastly, as our understanding of the molecular pathways
and gene-gene interactions improves, it is possible that
targeted molecular therapy may be available for a specific
genetic mutation that helps to ameliorate the patient’s
symptoms. For example, in individuals with vascular mal-
formations, somatic mutations in the AKT3-PI3K-mTOR
pathway have been identified. Some of these patients have
been successfully treated with mTOR-inhibitors such as
rapamycin [27, 28]. Our ability to offer such targeted ther-
apy will only improve with time as more high-throughput
drug screening methods are being deployed.
Gathering information
The process of ordering NGS starts with gathering a de-
tailed family history to determine if there are individuals
with similar or related phenotypes within the same fam-
ily, as well as to assess for possible inheritance pattern.
For example, multiple individuals in the same generation
and/or history of consanguinity will suggest a recessive
pattern, while having affected individuals in each gener-
ation would suggest a dominant pattern [4].
The next step is to perform detailed phenotyping of the
affected individual(s). These could include evaluations
from other subspecialists and/or performing biochemical
and/or radiological tests. For example, a child with a limb
anomaly would benefit from cardiac, gastrointestinal,
renal, and skeletal evaluations. With the phenotype and
pedigree information, a systematic review of literature or
syndrome database should be performed to exclude rare
but established syndromes [17]. This can then guide the
clinician on which gene(s) to test. In cases of genetic
heterogeneity, targeted NGS may be the preferred ap-
proach. On the other hand, if the disease mechanism is
unknown, WES may be the test of choice.
Pretest counseling and informed consent
It is imperative that a patient and his/her family are coun-
seled appropriately by a healthcare professional (such as aclinical geneticist or genetic counselor) who is aware of
the nuances of the test. It is important to maintain realistic
expectations for the patient and his/her family, as it is
possible that the testing may not return any positive
results. The diagnostic yield would differ on the test being
performed. In a targeted approach, it is possible that the
causal variant is in a gene that was not in the subset of
genes or regions that were targeted. On the other hand, as
the coverage in WES tends to be ~85–95 %, it is possible
that the causal variant lies in the region that was either
poorly covered or resides outside the protein-coding re-
gion of the gene (such as the promoter or regulatory
region) [17]. The sensitivity and limitations of the specific
NGS test must be clearly communicated.
It is also important to emphasize to the families that a
positive result may not change treatment or manage-
ment decisions, and hence, may not alter the prognosis
or outcome for the affected individual [17]. But it is also
possible that the test may identify targets that may be
amenable to certain medications. This has been the case
in the field of oncology, where specific molecular targets
are used to treat certain subtypes of cancer.
Cost remains an important consideration as clinical tar-
geted NGS or WES can cost between USD 2000 to 10,000
and USD 5000 to 15,000, respectively [17, 20]. Insurance
companies may not approve such costly tests, and in self-
payer healthcare systems (such as Singapore) where the
individual has to bear the cost, this may be prohibitively
expensive.
Lastly, the patient should be advised that variants
which are not related to the primary phenotype, also
referred to as secondary or incidental findings (IFs), may
be detected. Detection of IFs is more common with
WES and WGS and may be less of an issue with targeted
panels. This may have implications not only for the indi-
vidual, but also his/her family members [17, 20]. For
example, WES on a patient with intellectual disability
may detect pathogenic variants in BRCA1. This muta-
tion could be inherited from the parents, which would
mean that the affected parent (and his/her sibling) is at
risk of developing cancer and would require surveillance
and monitoring. This family may or may not be prepared
to receive such information and this should be discussed
during the informed consent process. While genetic
nondiscrimination act (GINA 2008) protects individuals
against discrimination in the USA, similar laws are lacking
in other countries [29]. Hence, individuals with a genetic
diagnosis, especially those with incidental findings, may
face discrimination at work or be denied medical insur-
ance without any avenue for legal redress.
In 2013, the American College of Medical Genetics
and Genomics (ACMG) recommended that laboratories
performing WES should report on incidental findings
detected in a minimum set of 56 genes. These 56 genes
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and include BRCA1 and BRCA2 [30]. In 2015, ACMG
updated the recommendations allowing patients and/or
parents to opt out of such analysis [31]. On the other
hand, the European Society of Human Genetics (ESHG)
advises for prudent use of WGS-based testing and to
restrict testing to regions of the genome linked to the
patient’s phenotype in order to avoid detection of such
incidental findings [32]. Even for exome or whole gen-
ome sequencing, it is possible to mask the results of
specific genes with a targeted workflow so that they are
excluded from subsequent analysis for variant identifica-
tion. Thus, physicians would not have to make the hard
decisions about the reporting of such incidental findings.
Interpretation of results
On average, ~60,000 to 100,000 variants are detected on
WES. These variants can be broadly classified into
pathogenic, benign, or variants of uncertain significance
(VUS). Pathogenic variants are defined as those variants
that adversely alter protein function and have either
been reported previously in other affected individuals or
have been shown to affect protein function in cellular or
animal models. These include variants such as nonsense,
frameshift, splicing, small insertion-deletions (indels), or
nonsynonymous missense variants. Benign variants, also
known as polymorphisms, are variants that exist in a sig-
nificant proportion of the population, including healthy
individuals, and account for majority of the variants de-
tected on NGS testing. These include synonymous mis-
sense variants, intronic, or intergenic variants [33].
VUS are variants that could possibly affect protein func-
tion based on in silico software (such as Polyphen-2 [34]
and SIFT [35, 36]) or other similar parameters, but either
have not been described in other individuals (affected or
unaffected) or do not have any functional analysis in other
model systems [33]. As there are genomic variations
across different populations and ethnic groups, a database
of common variants from healthy individuals is imperative
in understanding the significance of a given variant. Such
databases include dbSNP, 1000 Genomes project, Exome
Aggregation Consortium (ExAC), and Exome Sequencing
Project (ESP), but certain ethnicities are underrepresented
in these databases. Interpretation of VUS in such instances
requires segregation analysis (by analyzing the variant in
other family members)—presence of the variant in affected
but not in unaffected family members adds further evi-
dence to the possible causal relationship of a given variant.
An alternative approach includes testing the variant in
cellular and/or animal models, but this is beyond the
realms of a clinic or clinical laboratory and may be best
addressed through a research laboratory.
There is a wide range of possible outcomes with NGS
testing. Using WES, a single pathogenic variant that islikely to be the cause of the disease can be detected
about 20–36 % of the time [14–16, 37, 38]. For the
remainder of the cases, it is possible to either find mul-
tiple candidate variants or none at all. In the event that
multiple candidate variants are detected, segregation
analysis and/or functional analysis would help to deter-
mine the molecular etiology. If no candidate variants are
found, possibilities include poor coverage or the mutation
residing outside the protein-coding region of the gene or
the defect is not due to a simple nucleotide change in a
single gene.
Delivery of results
Clinicians should review the results of NGS and correl-
ate the findings with the relevant medical information.
When a pathogenic variant is detected in a gene that
explains the patient’s clinical phenotype, the clinician
should review the results as well as relevant clinical
information, including inheritance, prognosis, complica-
tions, or management, with the patient and his/her family.
Testing of at-risk individuals should be offered, when
possible.
On other occasions, finding of a particular variant may
prompt the clinician to look for additional history or
perform tests which may or may not support the conclu-
sion of the NGS test report. For example, in a patient
with chronic diarrhea, finding biallelic mutations in
TTC37 may prompt the clinician to review the hair for
specific features of trichorrhexis nodosa, suggestive of a
diagnosis of tricho-hepato-enteric syndrome [39]. On
the other hand, if more than one candidate variant is
detected, the clinician will need to perform further eval-
uation(s) to determine which of the variant is causing
the phenotype.
Lastly, if the test results are negative, reasons for this
should be discussed with the patient (as discussed in the
pretest counseling). In addition, as our understanding of
the human genome improves and more similar cases are
reported, there may be a possibility of associating the pa-
tient’s phenotype to a newly described genetic syndrome.
This requires reanalysis of the both clinical reports and
genetic data at regular intervals. However, regulations re-
garding who and how to perform reanalysis are currently
lacking and remain a challenge for the near future.
Future directions
Although disease-targeted testing may remain useful in
the short term, as our knowledge improves, addition of
newly identified genes to the panel (which has to be syn-
thesized according to customized order) may take time,
may be laborious and may not be cost-effective for the
laboratory. Many laboratories have now shifted to per-
forming WES and limiting the analysis to genes associ-
ated with phenotype and filling up the gaps with Sanger
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than targeted panel sequencing (which can go as high as
USD 3000 depending on the number of genes in the
panel), it allows for reanalysis of the data when new gene
associations are made. In addition, some commercial
companies have developed kits that capture only medic-
ally relevant regions of the genomes. These kits elimin-
ate the risk of finding variants in genes whose function
is unknown [20].
Currently, clinicians order NGS testing based on de-
tailed phenotyping and after excluding single candidate
genes—also referred to as a “phenotype first” approach.
As NGS testing becomes more easily available, there will
be a tendency for clinicians to perform the testing first
and then assess the patient’s phenotype to match the
genotype—referred to as “genotype first” approach [40].
It is also possible that in the not so distant future, a
relatively healthy individual may perform WES first and
then consult a clinician for interpretation of the findings
and subsequent evaluations. It may not be long before
newborns are screened for inherited disorders using
WES. However, there are many ethical, medical, and lo-
gistical challenges that need to be addressed before this
becomes common practice [20, 41].
Finally, there have been recent reports on the role of
somatic mutations in Mendelian diseases. This has been
advanced by the ability to perform deep-targeted NGS
to detect low level mutations in patients with Mendelian
disorders, majority of which would have been missed by
conventional testing [42]. As our understanding of the
role of somatic mutations in other human diseases in-
creases, deep-targeted NGS may be the test of choice in
these disorders.
Conclusion
NGS is a useful diagnostic test for the majority of Men-
delian disorders and is gaining acceptance in the medical
community. However, there remain certain key chal-
lenges that need to be addressed before NGS testing be-
comes part of routine clinical practice.
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